Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/58199
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKavaz Tufan, Aslı-
dc.contributor.authorBatibay, Fatma Ozak-
dc.contributor.authorAksoy, Gulsah Kaya-
dc.contributor.authorGulhan, Bora-
dc.contributor.authorKilic, Beltinge Demircioglu-
dc.contributor.authorDursun, Ismail-
dc.contributor.authorBuyukkaragoz, Bahar-
dc.date.accessioned2024-11-20T18:03:28Z-
dc.date.available2024-11-20T18:03:28Z-
dc.date.issued2024-
dc.identifier.issn2227-9067-
dc.identifier.urihttps://doi.org/10.3390/children11101164-
dc.identifier.urihttps://hdl.handle.net/11499/58199-
dc.description.abstractBackground/Objectives: Eculizumab is a first-line treatment for atypical hemolytic uremic syndrome (aHUS), and patients undergoing eculizumab therapy may become more susceptible to infection caused by Neisseria meningitidis (Nm). While meningococcal vaccination is required for patients undergoing eculizumab therapy, there is limited knowledge about meningococcal carriage in children with aHUS. We aimed to evaluate (1) the prevalence of Nm carriage, (2) serogroup distribution, and (3) the immunization status of children undergoing eculizumab treatment for aHUS. Methods: The Meningo-aHUS study is a prospective, multi-center study evaluating meningococcal carriage in children and adolescents in T & uuml;rkiye receiving eculizumab for aHUS. We noted the age, gender, daycare, school, or university attendance, passive smoking status, previous infection and antibiotic use, and previous immunization history, including meningococcal vaccines, from the medical records of those children with aHUS. We collected nasopharyngeal samples, tested them for Nm using real-time polymerase chain reaction, and performed a serogroup analysis on the positive samples. Results: We collected nasopharyngeal samples from 62 children with aHUS. Out of 62 children, 61 (98.4%) had received at least one dose of the meningococcal vaccine. The median time since the last meningococcal vaccine dose was 15 months (1-59 months). We detected meningococcal carriage in three (4.8%, 95% CI 1.0-13.5) children, and all three strains were non-groupable (NG). No other serogroups were detected. Conclusions: Almost all the children received their risk-group meningococcal immunization, including booster doses. A 4.8% of children with aHUS carried NG meningococci and, no vaccine serogroups were detected. Patients treated with eculizumab remain profoundly susceptible to IMD due to these NG meningococcal strains. The occurrence of breakthrough cases and carriage of Nm, especially NG strains, highlights the significance of maintaining a state of constant alertness, promptly seeking medical attention, and swiftly treating any symptoms that align with IMD, regardless of their vaccination status or antibiotic prophylaxis.en_US
dc.description.sponsorshipEskisehir Osmangazi University Research [THD-2024-3230]; Eskisehir Osmangazi Universityen_US
dc.description.sponsorshipThis study was financially supported by an Eskisehir Osmangazi University Research Grant (THD-2024-3230).en_US
dc.language.isoenen_US
dc.publisherMDPIen_US
dc.relation.ispartofChildren-Baselen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectatypical hemolytic uremic syndromeen_US
dc.subjecteculizumaben_US
dc.subjectNeisseria meningitidisen_US
dc.subjectchildrenen_US
dc.subjectmeningococcal vaccinesen_US
dc.subjectmeningococcien_US
dc.subjectnasopharyngeal colonizationen_US
dc.subjectWhole-Blooden_US
dc.subjectDiseaseen_US
dc.subjectRisken_US
dc.subjectEpidemiologyen_US
dc.subjectVaccinationen_US
dc.subjectExperienceen_US
dc.subjectSerumen_US
dc.titleMeningococcal Carriage in Children with Atypical Hemolytic Uremic Syndrome Receiving Eculizumab Therapyen_US
dc.typeArticleen_US
dc.identifier.volume11en_US
dc.identifier.issue10en_US
dc.departmentPamukkale Universityen_US
dc.authoridDinleyici, Ener Cagri/0000-0002-0339-0134-
dc.authoridNalcacioglu, Hulya/0000-0002-0686-9714-
dc.identifier.doi10.3390/children11101164-
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.authorscopusid57208493354-
dc.authorscopusid59388665500-
dc.authorscopusid56955138100-
dc.authorscopusid16244621000-
dc.authorscopusid57191333346-
dc.authorscopusid16021105100-
dc.authorscopusid36480824600-
dc.authorwosidNalcacioglu, Hulya/L-1713-2016-
dc.identifier.pmid39457129en_US
dc.identifier.scopus2-s2.0-85207704381en_US
dc.identifier.wosWOS:001343031900001en_US
dc.institutionauthor-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.openairetypeArticle-
item.fulltextNo Fulltext-
item.languageiso639-1en-
item.grantfulltextnone-
item.cerifentitytypePublications-
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection
Show simple item record



CORE Recommender

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.